Gender and age at the onset of disease don’t seem to have a clinically relevant impact on disability progression in people with primary progressive multiple sclerosis (PPMS), according to a recent study in Argentina. Disease progression, based on the Expanded Disability Status…
age
People over 60 with multiple sclerosis (MS) who have stable disease may discontinue their disease-modifying treatments (DMTs) without an added risk of relapses or worsening disability, according to a small study. At that age, only the presence of lesions with active inflammation and an Expanded Disability…
Among people with type 2 diabetes, the use of anti-hyperglycemic medications is associated with a reduced risk of multiple sclerosis (MS) for younger individuals, but an increased risk for older patients, particularly women. That’s according to the study “Age and sex differences on anti-hyperglycemic medication…
The first symptoms of relapsing-remitting multiple sclerosis (RRMS) have been appearing increasingly later in life, according to a Spanish study covering nearly five decades. From the 1970s through the 2010s, the average age at disease onset rose by more than 10 years in both men and women, its researchers…
Among people with multiple sclerosis (MS), a progressive disease type and the use of anti-CD20 therapies — such as ocrelizumab and rituximab — were associated with an increased risk of death from COVID-19, a new meta-analysis revealed. “We hope that these findings … may help neurologists in optimizing…
Worsening of Disability Evident in Older Patients Who Stop DMTs Some neurologists believe that multiple sclerosis (MS) progression slows, or even stops, when people reach their 60s, so they advise patients that there’s no need to continue their disease-modifying therapies (DMTs). Personally, I think a DMT age ceiling is…
While older multiple sclerosis (MS) patients whose conditions are stable commonly stop using disease-modifying therapies (DMTs), a study indicates this decision can shortly lead to a marked disease worsening in a substantial portion of them. “Our results raise important questions about the accepted practice of discontinuing medications once MS…
Taking the hormone melatonin may increase overall sleep quality in people with multiple sclerosis (MS), a clinical trial found. The compound, available as an over-the-counter dietary supplement, was particularly effective at extending sleep time in patients. Of note, sleep time decreased with age, meaning that “younger participants may have…
Inconsistently switching between hands for most common manual activities — or naturally choosing the left rather than the right hand — may be associated with more severe multiple sclerosis (MS), either in the form of younger age at diagnosis or progressive type, particularly in women, a small study suggests. These…
Among people with nervous system damage indicative of multiple sclerosis (MS), but who don’t yet have the disease — a condition known as radiologically isolated syndrome or RIS — the risk of progressing to full-fledged MS is higher for those who are younger, have spinal cord lesions, and have…
There is no link between serum vitamin D levels and the age at which an individual develops the first symptoms of multiple sclerosis (MS), a new observational study suggests. However, a link was found between cerebrospinal fluid antibody levels, serum vitamin D levels, and the age at first MS…
People with multiple sclerosis (MS) are not at greater risk for severe COVID-19 outcomes, according to a study of more than 150,000 hospitalized people in Germany. The study, “Multiple sclerosis is not associated with an increased risk for severe COVID-19: a nationwide retrospective cross-sectional study from Germany,” was…
Moderate-to-severe bowel dysfunction was detected in 14.5% of adult people with multiple sclerosis (MS), an Italian study reports. The prevalence of bowel dysfunction was increased in women and in patients with progressive forms of MS, higher disability, older age, and longer disease duration. Despite the prevalence of bowel dysfunction…
Nearly a third of people with multiple sclerosis (MS) who are younger than 40 are not being treated with disease-modifying treatments (DMTs), even though younger individuals are expected to get the most benefit from DMTs, according to a new study. “DMTs for MS are more frequently used at…
The prevalence of fatigue continues to be high among people with multiple sclerosis (MS) despite significant progress over the years in therapies that change the course of the disease, a large survey study in Norway found. The findings also show that the frequency of fatigue is higher in…
People with multiple sclerosis (MS) who have more extensive mobility issues are more likely to have worse outcomes from COVID-19, a new study indicates. The study findings also indicate that COVID-19-associated outcomes are worse among MS patients who are Black, older, have heart-related diseases, and who were treated with…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25-27. Go here to see all the latest stories from the conference. Factors in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord change with age and can affect…
Age is a main driver of disability in multiple sclerosis (MS) and has a key influence on patients’ therapeutic responses to Tecfidera (dimethyl fumarate) and Tysabri (natalizumab), a study showed. Given those findings, age should be considered in the risk/benefit assessment that’s used in the decision-making process for…
A bone marrow transplant may be particularly useful for those with relapsing forms of multiple sclerosis (MS) who, despite treatment with high-efficacy disease-modifying therapies (DMTs), continue to experience relapses or show signs of new lesions, experts say. According to new recommendations from the National Multiple Sclerosis Society,…
The use of disease-modifying therapies (DMTs) in adults with multiple sclerosis (MS) increased the risk of precancerous growth in those older than 45 years of age, according to an age-related adverse events analysis of several dozen clinical trials. …
Oral administration of trehalose — a sugar molecule found in plants and fungi and reported to have neuroprotective effects — eased symptoms and halted disease progression in a mouse model of multiple sclerosis (MS). These benefits were associated with a restoration of the ability of microglia (the brain’s immune cells) to break down…
Older age at disease-modifying therapy (DMT) discontinuation is the main predictive factor of sustained “no evidence of disease activity” (NEDA) in people starting DMT immediately after being diagnosed with clinically isolated syndrome (CIS), according to a study in Austria. In particular, patients discontinuing DMT at age 45 or…
Longer exposure to disease-modifying therapies (DMTs) may delay disability progression and the time until people with primary progressive multiple sclerosis (PPMS) require the aid of a wheelchair, an Italian registry-based study found. The study also suggests that starting treatment with DMTs — medications that reduce the activity of…
In people with multiple sclerosis (MS) under age 50, the presence of cardiovascular risk factors is associated with a greater loss of brain volume, including white and grey matter, a study showed. The brain’s white matter mainly consists of nerve fibers and is typically affected by MS, while…
Children with multiple sclerosis (MS) recover more quickly and “significantly better” from relapses than do adults — patients with disease onset at age 18 or older, researchers reported. The study, “Improved relapse recovery in paediatric compared to adult multiple sclerosis,” was published in the journal Brain. Relapses and…
More than half of people with brain imaging changes akin to multiple sclerosis (MS) go on to develop the disease within 10 years, a global study of those with radiologically isolated syndrome reported. Progression to MS appears to be more likely in those who are younger, have spinal…
Exposure to disease-modifying therapies does not increase multiple sclerosis (MS) patients’ risk of developing a severe form of COVID-19, according to a registry-based study. However, MS patients who are older, obese, or have severe neurological impairments have a greater risk of developing a severe form of the disease. Findings…
Older age, a greater number of health conditions, and prior hospital admissions are associated with more hospitalizations due to all causes among people with multiple sclerosis (MS). However, MS-related hospitalizations decrease as patients age, and are less frequent among women, according to a study analyzing more than two decades…
Sexual dysfunction is prevalent among women with multiple sclerosis (MS), and one way physicians can help improve their patients’ quality of life is to ask them about the problem. That finding is detailed in the study “Sexual dysfunction in women with multiple sclerosis: prevalence and impact on…
Women with multiple sclerosis (MS) who have never given birth and those who began menopause prematurely tend to develop progressive forms of the disease earlier, a study from the Mayo Clinic suggests. These findings were presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum…